Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation

Assessment of efficacy and safety UK-390,957.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ejaculation

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Pfizer Investigational Site, Bondi Junction, New South Wales, Australia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Premature ejaculation as defined by DSM-IV

Exclusion criteria

History of erectile dysfunction

Treatment and study plan

UK-390,957

Drug

Primary outcomes

Assessment of efficacy and safety

Secondary outcomes

Assessment of quality of sexual life

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation

Important dates

Study start: 2004
Primary completion: 2005
Study completion: 2005
First posted: Sep 22, 2005
Registry last updated: Nov 7, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed